PR Newswire Clinical TrialsOriginal article
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
Data ReadoutpositivebempikibartPositive
AI Analysis
Summary
Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA trial of bempikibart in alopecia areata, demonstrating clinically meaningful efficacy with 35.3% mean reduction in SALT score and 40.0% of patients achieving SALT-20 response.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
Clinically meaningful efficacy data observed on primary endpoint with 35.3% mean percent reduction in SALT score from baseline in mITT analysis; 40.0% of patients achieved SALT-20 response at Week 36
Importance:7/10
Sentiment:
0.85
alopecia areataclinical trialtopline resultsefficacy dataSIGNAL-AA trial
Read the original article
Published by PR Newswire Clinical Trials on July 13, 2026 10:59 AM